GSK catalyst calendar

GSK plc

Upcoming catalysts
18
Cash runway
Cash generating
Cash & investments
GBP 3397M
Phase 3 programs
26

GSK plc is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer on November 2, 2026. There are 18 upcoming events on record.

GSK plc generates cash from operations, so a burn-based runway figure does not apply.

Across 410 concluded trials, 91% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 2, 2026 A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer Trial Milestone Phase 2
November 17, 2026 A Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With Ganfeborole in Female Participants of Non-childbearing Potential Trial Milestone Phase 1
December 3, 2026 A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults Trial Milestone Phase 1
December 14, 2026 A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age Trial Milestone Phase 3
December 28, 2026 A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study Trial Milestone Phase 2
December 31, 2026 Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors Trial Milestone Phase 1
August 5, 2027 A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care Trial Milestone Phase 1
August 23, 2027 A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults Trial Milestone Phase 3
October 24, 2027 A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China Trial Milestone Phase 2
October 29, 2027 Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial Trial Milestone Phase 3
February 14, 2028 A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors Trial Milestone Phase 1
February 29, 2028 A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) Trial Milestone Phase 3
August 11, 2028 A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD) Trial Milestone Phase 2
May 4, 2029 A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events Trial Milestone Phase 2
May 4, 2029 A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2) Trial Milestone Phase 3
December 12, 2029 A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer Trial Milestone Phase 3
April 1, 2030 A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland Trial Milestone Phase 4
August 30, 2030 A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer Trial Milestone Phase 4

Track GSK alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open GSK in the tracker

Recent history

DateEventTypePhase
October 14, 2026 6-K filed: Corporate announcement Corporate —
October 13, 2026 6-K filed: Corporate announcement Corporate —
October 13, 2026 6-K filed: Corporate announcement Corporate —
October 8, 2026 6-K filed: Corporate announcement Corporate —
October 6, 2026 6-K filed: Foreign issuer report Filing —
October 1, 2026 6-K filed: Foreign issuer report Filing —
September 29, 2026 Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Trial Milestone Phase 3
September 24, 2026 6-K filed: Corporate announcement Corporate —
September 22, 2026 6-K filed: Corporate announcement Corporate —
September 15, 2026 6-K filed: Foreign issuer report Filing —
September 15, 2026 6-K filed: Foreign issuer report Filing —
September 14, 2026 6-K filed: Clinical or regulatory announcement Filing —
September 14, 2026 6-K filed: Clinical or regulatory announcement Filing —
September 11, 2026 6-K filed: Corporate announcement Corporate —
September 10, 2026 6-K filed: Clinical or regulatory announcement Filing —
September 10, 2026 6-K filed: Corporate announcement Corporate —
September 10, 2026 A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 Trial Milestone Phase 2
September 9, 2026 6-K filed: Corporate announcement Corporate —
September 9, 2026 6-K filed: Corporate announcement Corporate —
September 8, 2026 6-K filed: Foreign issuer report Filing —
September 1, 2026 6-K filed: Clinical or regulatory announcement Filing —
September 1, 2026 6-K filed: Foreign issuer report Filing —
August 26, 2026 6-K filed: Corporate announcement Corporate —
August 24, 2026 6-K filed: Clinical or regulatory announcement Filing —
August 24, 2026 6-K filed: Clinical or regulatory announcement Filing —
August 24, 2026 6-K filed: Corporate announcement Corporate —
August 18, 2026 6-K filed: Corporate announcement Corporate —
August 13, 2026 6-K filed: Corporate announcement Corporate —
August 11, 2026 6-K filed: Corporate announcement Corporate —
August 3, 2026 6-K filed: Foreign issuer report Filing —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.